Evidence map›Paper›PMID 32699879›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021

Phage Therapy for Limb-threatening Prosthetic Knee Klebsiella pneumoniae Infection: Case Report and In Vitro Characterization of Anti-biofilm Activity.

Edison J Cano, Katherine M Caflisch, Paul L Bollyky, Jonas D Van Belleghem, Robin Patel, Joseph Fackler, Michael J Brownstein, Bri'Anna Horne, Biswajit Biswas, Matthew Henry and 3 more

Open access · greenAbstract readCase Reports
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 154 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
154citing papers in PubMed, 5 pooled it
24.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

154 citing papers in PubMed, 5 syntheses or guidelines pooled it, 236 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Review
  8. Article
  9. AcuteThe Journal of international medical research · 2026
    Article
  10. [Bacteriophage Therapy in Orthopaedics and Trauma].Acta chirurgiae orthopaedicae et traumatologiae Cechoslovaca · 2026
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. The Role of PositivePathogens (Basel, Switzerland) · 2026
    Article
  16. Article
  17. Article
  18. Review
  19. Bacteriophage Therapy AgainstMicroorganisms · 2026
    Review
  20. Review

94 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Edison J CanoDivision of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Katherine M CaflischInfectious Diseases Research Laboratory, Mayo Clinic, Rochester, Minnesota, USA.
Paul L BollykyDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
Jonas D Van BelleghemDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
Robin PatelDivision of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Joseph FacklerAdaptive Phage Therapeutics, Gaithersburg, Maryland, USA.
Michael J BrownsteinAdaptive Phage Therapeutics, Gaithersburg, Maryland, USA.
Bri'Anna HorneAdaptive Phage Therapeutics, Gaithersburg, Maryland, USA.
Biswajit BiswasGenomics and Bioinformatics Department, Biological Defense Research Directorate, Naval Medical Research Center-Frederick, Fort Detrick, Maryland, USA.
Matthew HenryGenomics and Bioinformatics Department, Biological Defense Research Directorate, Naval Medical Research Center-Frederick, Fort Detrick, Maryland, USA.
Francisco MalagonGenomics and Bioinformatics Department, Biological Defense Research Directorate, Naval Medical Research Center-Frederick, Fort Detrick, Maryland, USA.
David G LewallenDepartment of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA.
Gina A SuhDivision of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Mayo Clinic in Florida · USNaval Medical Research Command · USMayo Clinic · USStanford University · US

Funding

Mayo Clinic Center for Clinical and Translational Science (CCaTS UL1 Supplement - Dr. Timothy Curry)UL1TR002377 · NCATS · MAYO CLINIC ROCHESTER · PI VESNA D GAROVIC · 2017 to 2026
$78.4M
Molecular Detection of Biofilms on Hip and Knee ImplantsR01AR056647 · NIAMS · MAYO CLINIC ROCHESTER · PI PATEL, ROBIN · 2009 to 2020
$4.5M
NCATS NIH HHS UL1 TR002377NIAMS NIH HHS R01 AR056647
6 · The paper itself

Abstract

backgroundProsthetic joint infection (PJI) is a potentially limb-threatening complication of total knee arthroplasty. Phage therapy is a promising strategy to manage such infections including those involving antibiotic-resistant microbes, and to target microbial biofilms. Experience with phage therapy for infections associated with retained hardware is limited. A 62-year-old diabetic man with a history of right total knee arthroplasty 11 years prior who had suffered multiple episodes of prosthetic knee infection despite numerous surgeries and prolonged courses of antibiotics, with progressive clinical worsening and development of severe allergies to antibiotics, had been offered limb amputation for persistent right prosthetic knee infection due to Klebsiella pneumoniae complex. Intravenous phage therapy was initiated as a limb-salvaging intervention.

methodsThe patient received 40 intravenous doses of a single phage (KpJH46Φ2) targeting his bacterial isolate, alongside continued minocycline (which he had been receiving when he developed increasing pain, swelling, and erythema prior to initiation of phage therapy). Serial cytokine and biomarker measurements were performed before, during, and after treatment. The in vitro anti-biofilm activity of KpJH46Φ2, minocycline and the combination thereof was evaluated against a preformed biofilm of the patient's isolate and determined by safranin staining.

resultsPhage therapy resulted in resolution of local symptoms and signs of infection and recovery of function. The patient did not experience treatment-related adverse effects and remained asymptomatic 34 weeks after completing treatment while still receiving minocycline. A trend in biofilm biomass reduction was noted 22 hours after exposure to KpJH46Φ2 (P = .063). The addition of phage was associated with a satisfactory outcome in this case of intractable biofilm-associated prosthetic knee infection. Pending further studies to assess its efficacy and safety, phage therapy holds promise for treatment of device-associated infections.

Indexed as

Arthroplasty, Replacement, KneePhage TherapyProsthesis-Related InfectionsAnti-Bacterial AgentsBiofilmsHumansKlebsiella pneumoniaeMaleMiddle AgedAnti-Bacterial Agentsarthroplastybacteriophage therapybiofilmphage therapyprosthetic joint infection

Identifiers

PMID32699879
PMCPMC8246933
OpenAlexW3045118558

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.